MedTrace Logo

Normalizing Antibody Detection in First-void Urine

NCT06582654 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-09-03

No results posted yet for this study

Summary

The aim of this study is to develop robust analytical protocols for the monitoring of vaccine induced immunity against the Human Papillomavirus (HPV) in first-void urine samples and to examine fluctuations of urinary HPV-specific antibodies and potential normalization markers in different cohorts.

Conditions

  • Human Papillomavirus Infection

Interventions

DEVICE

Sampling

Collection of first-void urine (i.e. the initial stream of the urine) with the Colli-Pee device (Novosanis, Belgium) (6-21 samples over a period of 36 days). Collection of blood samples (2 samples, at day 1 and 36 of the study).

Sponsors & Collaborators

  • University Hospital, Antwerp

    collaborator OTHER

  • Universiteit Antwerpen

    lead OTHER

Principal Investigators

  • Wiebren Tjalma, MD · University Hospital, Antwerp

Eligibility

Min Age
9 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-07
Primary Completion
2026-01-01
Completion
2026-01-01

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06582654 on ClinicalTrials.gov